Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Novartis
Harvard Business School
Fish and Richardson
AstraZeneca
Johnson and Johnson
Queensland Health
US Department of Justice
Deloitte
Baxter

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,658,676

« Back to Dashboard

Which drugs does patent 8,658,676 protect, and when does it expire?


Patent 8,658,676 protects CLEVIPREX and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 8,658,676

Title:Clevidipine emulsion formulations containing antimicrobial agents
Abstract: Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.
Inventor(s): Motheram; Rajeshwar (Dayton, NJ), Williams; Gregory Charles (Bernardsville, NJ)
Assignee: The Medicines Company (Parsippany, NJ)
Application Number:13/765,613
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeY
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeY
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,658,676

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand610465► Subscribe
Mexico2013004151► Subscribe
South Korea20160032266► Subscribe
South Korea20130101080► Subscribe
Japan2016183183► Subscribe
Japan2014196322► Subscribe
Japan6040437► Subscribe
Japan2014504259► Subscribe
HungaryE026295► Subscribe
Hong Kong1187495► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Deloitte
Cantor Fitzgerald
Harvard Business School
Teva
Julphar
Fuji
Moodys
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot